tradingkey.logo

Pluri Inc

PLUR
View Detailed Chart

4.600USD

+0.098+2.18%
Close 09/19, 16:00ETQuotes delayed by 15 min
36.31MMarket Cap
LossP/E TTM

Pluri Inc

4.600

+0.098+2.18%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.18%

5 Days

-6.82%

1 Month

+2.00%

6 Months

+2.45%

Year to Date

+7.60%

1 Year

-15.83%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and strong technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
141 / 506
Overall Ranking
249 / 4720
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Buy
Current Rating
12.000
Target Price
+166.55%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 365.51% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.34M.
Fairly Valued
The company’s latest PE is -1.27, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.98M shares, increasing 9.41% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 27.42K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.76.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Ticker SymbolPLUR
CompanyPluri Inc
CEOMr. Yaky Yanay
Websitehttps://pluri-biotech.com/
KeyAI